|1.||Rajsiglova, Lenka: 1 article (01/2015)|
|2.||Canese, Rossella: 1 article (01/2015)|
|3.||Krizan, Jiri: 1 article (01/2015)|
|4.||Carbo, Miriam: 1 article (01/2015)|
|5.||Boffi, Alberto: 1 article (01/2015)|
|6.||Cecchetti, Serena: 1 article (01/2015)|
|7.||Carpinelli, Giulia: 1 article (01/2015)|
|8.||Failla, Cristina Maria: 1 article (01/2015)|
|9.||Stakheev, Dmitry: 1 article (01/2015)|
|10.||Fornara, Manuela: 1 article (01/2015)|
|1.||Melanoma (Melanoma, Malignant)
11/01/1994 - "Radioreceptor binding studies have documented the presence of melanotropin receptors on some but not all of the various human melanoma cell lines that have been studied. "
02/15/1990 - "The methods described will be applicable for studies of the expression and regulation of MSH receptors in human melanoma and other target tissues."
01/01/2014 - "The purified MSH-PE38KDEL was found to be selectively cytotoxic to MSH receptor-positive melanoma cells in vitro. "
04/01/2012 - "When stably expressed in HEK293/FRT cells or in B16-G4F mouse melanoma cells (an MSH receptor-deficient cell clone), MRAPα and MRAPdCT (truncated MRAP1, N-terminal only) localized mainly around the nuclear envelope and within dense intracellular endosomes, while MRAPβ exhibited a strong localization at the plasma membrane, and partially with rapid recycling endosomes. "
06/01/2003 - "These modular transporters delivered PSs into the nuclei, the most vulnerable sites for the action of PSs, of murine melanoma cells, but not non-MSH receptor-overexpressing cells, to result in cytotoxic effects several orders of magnitude greater than those of nonmodified PSs. "
04/01/1993 - "MSH receptors and function in amelanotic B16 melanoma cells."
05/01/1992 - "MSH receptor expression and the relationship to melanogenesis and metastatic activity in B16 melanoma."
11/01/1996 - "Binding and internalization of the melanocyte stimulating hormone receptor ligand [Nle4, D-Phe7] alpha-MSH in B16 melanoma cells."
11/01/1996 - "The current study aims to ascertain the fate of the melanocyte stimulating hormone (MSH) receptor and its ligand [Nle4, D-Phe7] alpha-MSH (NDP-MSH) following binding to murine B16 melanoma cells. "
11/15/1989 - "Cross-linking of the alpha-MSH-receptor complex of three cell lines using monoiodinated [Nle4,D-Phe7,Trp(2-nitro-4-azidophenylsulfenyl)9]-alpha-MSH as photoaffinity label revealed a major Mr 45,000 protein band on sodium dodecyl sulfate-polyacrylamide gels, analogous to the MSH receptor of mouse B16 melanoma cells."
|3.||Neoplasm Metastasis (Metastasis)
01/01/1995 - "Transcriptional induction of the melanocyte-stimulating hormone receptor in brain metastases of murine K-1735 melanoma."
05/01/1992 - "In this study we have compared the effects of different pro-opiomelanocortin (POMC) peptides on melanogenesis and metastasis and their relationship to MSH receptor expression in B16F1 melanoma cells. "
05/01/1992 - "Since previous work has shown that melanotropin receptors are detectable in melanoma metastases of about 80% of human patients, malignant melanoma cells of many patients may be susceptible to killing by the melanotropin receptor-targeted cytotoxin DAB389-MSH."
05/01/1992 - "Interaction of an alpha-melanocyte-stimulating hormone-diphtheria toxin fusion protein with melanotropin receptors in human melanoma metastases."
05/01/1992 - "In the present study, binding of DAB389-MSH to melanotropin receptors in biopsy specimens of human and mouse melanoma metastases was assessed by measuring its ability to inhibit binding of a radiolabeled, superpotent analogue of alpha-MSH (125I-[Nle4,D-Phe7]-alpha-MSH; 125I-NDP-MSH) and comparing its potency in this system with those of the established ligands NDP-MSH and alpha-MSH. "
01/01/2014 - "In conclusion, MSH-PE38KDEL had cytotoxic effects on MSH receptor-positive melanoma cells, and causes significant tumor growth inhibition. "
02/15/1990 - "Melanotropin receptors of murine melanoma characterized in cultured cells and demonstrated in experimental tumors in situ."
12/01/1995 - "This article summarizes recent reports from our laboratory and others demonstrating that the organ microenvironment can profoundly influence the pattern of gene expression and the biological phenotype of metastatic tumor cells, including induction of melanocyte stimulating hormone receptor and production of melanin, regulation of terminal differentiation and apoptosis, resistance to chemotherapy, and regulation of growth at the organ-specific metastatic site. "
01/01/2015 - "Furthermore, HFt-MSH-PEG NPs accumulated to a significantly lower extent and with a different distribution in a diverse type of tumor (TS/A adenocarcinoma), which does not express α-MSH receptors. "
01/01/1995 - "The production of melanin in tumor cells growing in the brain was directly correlated with induction of melanocyte-stimulating hormone receptor (MSH-R) steady-state mRNA transcripts. "
|5.||Lung Neoplasms (Lung Cancer)
02/01/1997 - "Specificity of the binding of melanocytes to the melanotropin-conjugated macrospheres was demonstrated by several studies: (i) Binding of melanocytes to the conjugate was specific since it could be blocked by prior incubation of the cells in the presence of the unconjugated hormone analog; (ii) The macrospheres after removal of the bound ligand did not bind to the melanocytes; (iii) Another peptide hormone ligand (e.g., a substance-P analog) attached to the macrospheres failed to bind to the melanocytes; (iv) B16/F10 mouse melanoma cells known to express melanotropin receptors bound to the macrospheres; (v) Cells of nonmelanocyte origin (e.g., mammary cancer cells, lung cancer cells, fibroblasts) did not bind to the macrospheres. "
|2.||Melanocyte-Stimulating Hormones (MSH)
|8.||Adrenocorticotropic Hormone (ACTH)
|10.||Adenosine Monophosphate (AMP)
|2.||Drug Therapy (Chemotherapy)